Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Sitagliptin. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102503829A reveals a mild Grignard route for sitagliptin intermediates, offering cost-effective and scalable manufacturing solutions for global pharma supply chains.
Patent CN107312010A reveals a high-yield sitagliptin synthesis route. Offers cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN111411095B discloses a novel recombinant (R)-ω-transaminase mutant with high activity and stereoselectivity for efficient sitagliptin intermediate production, ensuring supply chain stability.
Patent CN112094856B discloses high-efficiency transaminase mutants for sitagliptin synthesis, achieving >99.95% e.e. and enabling significant cost reduction in API manufacturing.
High-yield sitagliptin intermediate preparation method patent analysis. Supply chain stability and cost optimization for pharmaceutical manufacturing partners.
Patent CN105330664B reveals high-purity Sitagliptin impurity synthesis. Offers cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN113149991A details a safer sitagliptin synthesis avoiding DMF and chromatography. Discover cost-effective manufacturing and high-purity supply solutions.
Patent CN102093245B details a cost-effective Suzuki coupling route for Sitagliptin intermediates. This method enhances supply chain reliability and reduces dependency on expensive noble metal catalysts for pharmaceutical manufacturing.
Novel enzymatic route for Sitagliptin key intermediate reduces costs and eliminates heavy metals. Ideal for reliable pharmaceutical intermediate suppliers seeking scalable API manufacturing solutions.
Patent CN110951706B details a high-activity R-omega-TA mutant for sitagliptin. Offers high ee value >99%, breaking technical monopolies and ensuring supply chain stability.
Novel aminotransferase mutants enable high-yield sitagliptin synthesis. Cost-effective, scalable pharma intermediate solution with >99% ee.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN117701523A reveals solvent-tolerant transaminase for high-purity sitagliptin intermediate manufacturing with significant supply chain cost reduction.
Patent CN113061594A reveals novel immobilized transaminase mutants for sitagliptin synthesis, offering superior stability in aqueous isopropanol and reduced manufacturing costs.
Patent CN113061594A details a robust immobilized transaminase process for sitagliptin intermediates, offering superior stability and simplified solvent systems for cost-effective API manufacturing.
Novel synthetic route for Sitagliptin avoiding expensive catalysts. High yield, scalable process for pharmaceutical intermediates. Cost-effective manufacturing solution.
Novel patent method ensures high purity Sitagliptin free base with significant cost reduction and supply chain reliability for global pharmaceutical manufacturers.
Novel (R)-ω-transaminase mutant enables high-conversion synthesis of Sitagliptin intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Patent CN107384887A reveals high-purity Sitagliptin synthesis via aminotransferase. Achieves 99% ee and 76% yield, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN111411094B discloses a novel mutant enzyme achieving 95.4% conversion at high substrate concentrations, offering significant cost reduction in API manufacturing.